All is not lost: learning from 9p21 loss in cancer

Spiliopoulou, P. , Yang, S.Y. C., Bruce, J. P., Wang, B. X., Berman, H. K., Pugh, T. J. and Siu, L. L. (2022) All is not lost: learning from 9p21 loss in cancer. Trends in Immunology, 43(5), pp. 379-390. (doi: 10.1016/j.it.2022.03.003) (PMID:35379580)

Abstract

The cancer research community continues to search for additional biomarkers of response and resistance to immune checkpoint treatment (ICT). The ultimate goal is to direct the use of ICT in patients whose tumors are most likely to benefit to achieve a refinement that is equivalent to that of a genotype-matched targeted treatment. Dissecting the mechanisms of ICT resistance can help us characterize ICT nonresponders more efficiently. In this opinion, we argue that there may be additional knowledge gained about immune evasion in cancer by analyzing the loss of the human 9p21.3 locus; as an example, we highlight findings of 9p21.3 loss from the investigator-initiated, pan-cancer INSPIRE study, in which patients were treated with pembrolizumab (anti-PD-1 antibody) ICT.

• Item Type: Articles
• Additional Information: This work was supported by funds provided by the Princess Margaret Cancer Foundation, Ontario Institute for Cancer Research, and Terry Fox Research Institute. We gratefully acknowledge Merck for contributing the study drug for the INSPIRE clinical trial. T.J.P. is supported by a Senior Investigator Award from the Ontario Institute for Cancer Research, a Canada Research Chair in Translational Genomics and the Gattuso-Slaight Personalized Cancer Medicine Fund at the Princess Margaret Cancer Centre. L.L.S. is supported, in part, by the BMO Chair in Precision Cancer Genomics. P.S. is supported, in part, by the Hold’em for Life Oncology Fellowship (University of Toronto).
• Status: Published
• Refereed: Yes
• Glasgow Author(s) Enlighten ID: Spiliopoulou, Dr Pavlina
• Authors: Spiliopoulou, P., Yang, S.Y. C., Bruce, J. P., Wang, B. X., Berman, H. K., Pugh, T. J., and Siu, L. L.
• College/School: College of Medical Veterinary and Life Sciences > School of Cancer Sciences
• Journal Name: Trends in Immunology
• ISSN: 1471-4906
• ISSN (Online): 1471-4981
• Published Online: 01 April 2022
• Copyright Holders: Copyright © 2022 The Author(s)
• First Published: First published in Trends in Immunology 43(5):379-390
• Publisher Policy: Reproduced under a Creative Commons licence